Skip to content

Application of the "Tongdu Tiaoshen" Method for Insomnia Treatment in Breast Cancer Survivors: A Clinical Study on Governor Vessel Moxibustion Therapy

Application of the "Tongdu Tiaoshen" Method for Insomnia Treatment in Breast Cancer Survivors: A Clinical Study on Governor Vessel Moxibustion Therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000578
Enrollment
Unknown
Registered
2024-10-21
Start date
2025-03-01
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer-related insomnia

Interventions

waitlist control group:Standard Care
Governor Vessel Moxibustion Group:Standard Care + Governor Vessel Moxibustion

Sponsors

Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Age between 18 and 75 years; 2) Female patients diagnosed with stage I-III breast cancer; 3) Completion of primary breast cancer treatment (surgery radiotherapy chemotherapy targeted therapy immunotherapy) for at least 3 months with ongoing endocrine therapy permitted if duration exceeds 3 weeks; 4) No evidence of cancer recurrence or new primary tumors; 5) Meets the diagnostic criteria for insomnia as defined in the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) published by the American Psychiatric Association (APA); 6) Mild to severe insomnia defined by an Insomnia Severity Index (ISI) score ranging from 8 to 21.

Exclusion criteria

Exclusion criteria: 1) Presence of other sleep disorders (e.g. obstructive sleep apnea parasomnias narcolepsy); 2) Shift work or Irregular sleep habits; 3) Presence of severe medical conditions or health issues that could impede full participation in the study; 4) Pregnant or breastfeeding women.

Design outcomes

Primary

MeasureTime frame
Insomnia Severity Index;

Secondary

MeasureTime frame
serum inflammatory cytokines (interleukin-1ß interleukin-6 and tumor necrosis factor-a);gut microbiota;serum melatonin levels;serum hormones related to the hypothalamic-pituitary-adrenal (HPA) axis [adrenocorticotropic hormone (ACTH) corticotropin-releasing hormone (CRH) and cortisol (CORT);cores on the Functional Assessment of Cancer Therapy-Breast (FACT-B) scale;usage of hypnotic medications;serum neurotransmitters (5-hydroxytryptamine and gamma-aminobutyric acid);fecal short-chain fatty acids;serum metabolites;

Countries

China

Contacts

Public ContactBing Lin

Health Management Center Hospital of Chengdu University of Traditional Chinese Medicine

linbingkeyan@gmail.com13541229930

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026